gopubmed logo
find other proteinsAll proteins
GoPubMed Proteins lists recent and important papers and reviews for proteins. Page last changed on 19 Aug 2016.

Cyclin-dependent kinase 4

CDK4, Cyclin-Dependent Kinase 4
The protein encoded by this gene is a member of the Ser/Thr protein kinase family. This protein is highly similar to the gene products of S. cerevisiae cdc28 and S. pombe cdc2. It is a catalytic subunit of the protein kinase complex that is important for cell cycle G1 phase progression. The activity of this kinase is restricted to the G1-S phase, which is controlled by the regulatory subunits D-type cyclins and CDK inhibitor p16(INK4a). This kinase was shown to be responsible for the phosphorylation of retinoblastoma gene product (Rb). Mutations in this gene as well as in its related proteins including D-type cyclins, p16(INK4a) and Rb were all found to be associated with tumorigenesis of a variety of cancers. Multiple polyadenylation sites of this gene have been reported. [provided by RefSeq, Jul 2008] (from NCBI)
Top mentioned proteins: PCNA, p21, CAN, CDK6, CDK2
Papers using CDK4 antibodies
Evaluation of the anti-inflammatory and anti-proliferation tumoral cells activities of Antrodia camphorata, Cordyceps sinensis, and Cinnamomum osmophloeum bark extracts
Hseu You-Cheng et al., In Evidence-based Complementary and Alternative Medicine : eCAM, 2006
... , caspase-3, caspase-9, cyclin D1, and CDK4 were obtained from Cell Signaling Technology, Inc ...
Novel approaches for targeted cancer therapy
Kawakami Koji et al., In Journal of Translational Medicine, 2003
... Anti-Akt and anti-CDK4 antibodies were purchased from Cell Signaling.
Slamon Dennis J et al., In Breast Cancer Research, 2003
... and cdk4 (C-22) were purchased from Santa Cruz Biotechnology (Santa Cruz, CA, USA) ...
Destabilization of steroid receptors by heat shock protein 90-binding drugs: a ligand-independent approach to hormonal therapy of breast cancer.
Ahmad Aamir, In PLoS ONE, 2000
... Anti-Poly(ADP-ribose)polymerase, anti-caspase-3, anti-Raf-1, anti-CDK4 antibodies were from Santa Cruz Biotechnology Inc ...
STAT3 mediates the survival signal in oncogenic ras-transfected intestinal epithelial cells
Peng Jun et al., In International Journal of Molecular Sciences, 1997
... PCNA, Bcl-2, Bax, P21, cyclinD1, CDK4 antibodies, horseradish peroxidase (HRP)-conjugated secondary anti-bodies were obtained from Cell Signaling (Beverly, MA, USA) ...
more suppliers
Papers on CDK4
Multiple primary melanomas (MPMs) and criteria for genetic assessment: MultiMEL, a multicenter study of the Italian Melanoma Intergroup.
Bianchi-Scarrà et al., Genova, Italy. In J Am Acad Dermatol, Feb 2016
OBJECTIVE: We sought to determine the CDKN2A/CDK4/microphthalmia-associated transcription factor mutation rate among Italian patients with MPM to appropriately direct genetic counseling regardless of family history.
Anti-tumor role of Bacillus subtilis fmbJ-derived fengycin on human colon cancer HT29 cell line.
Wang et al., In Neoplasma, Feb 2016
The effects of fengycin on Bax/Bcl-2, CDK4/cyclin D1, Caspase-6 and Caspase-3 expressions in HT29 cells were analyzed using western blot.
Phosphorylated retinoblastoma protein is a potential predictive marker of irinotecan efficacy for colorectal cancer.
Sakai et al., Kyoto, Japan. In Int J Oncol, Feb 2016
Intriguingly, the knockdown of both CDK4 and CDK6, but not CDK2, allowed RB to become the most hypophosphorylated form and converted the SN38-sensitive cells to a resistant state.
Giant Scrotal Fibrolipoma.
Sountoulides et al., Thessaloníki, Greece. In Rare Tumors, Jan 2016
On immunohistochemistry, MDM2 and CDK4 were not expressed.
The Challenge of Cancer Genomics in Rare Nervous System Neoplasms: Malignant Peripheral Nerve Sheath Tumors as a Paradigm for Cross-Species Comparative Oncogenomics.
Carroll, Charleston, United States. In Am J Pathol, Jan 2016
Studies of human neurofibromatosis type 1-associated tumors suggest that NF1 tumor suppressor loss in Schwann cells triggers cell-autonomous and intercellular changes, resulting in development of benign neurofibromas; subsequent neurofibroma-MPNST progression is caused by aberrant growth factor signaling and mutations affecting the p16(INK4A)-cyclin D1-CDK4-Rb and p19(ARF)-Mdm2-p53 cell cycle pathways.
Targeting CDK4 and CDK6: From Discovery to Therapy.
Shapiro et al., London, United Kingdom. In Cancer Discov, Jan 2016
UNASSIGNED: Biochemical and genetic characterization of D-type cyclins, their cyclin D-dependent kinases (CDK4 and CDK6), and the polypeptide CDK4/6 inhibitor p16(INK4) over two decades ago revealed how mammalian cells regulate entry into the DNA synthetic (S) phase of the cell-division cycle in a retinoblastoma protein-dependent manner.
Knockdown of receptor tyrosine kinase-like orphan receptor 2 inhibits cell proliferation and colony formation in osteosarcoma cells by inducing arrest in cell cycle progression.
Wu et al., Jishou, China. In Oncol Lett, Dec 2015
Mechanistic investigation revealed that the protein levels of c-myc, a target gene of the Wnt signaling, as well as cyclin D1, cyclin E and cyclin-dependent kinase 4 were markedly reduced in the ROR2-knockdown OS cells, suggesting that the inhibitory effect of ROR2 knockdown on OS cell proliferation is associated with the Wnt signaling pathway.
CDK6-a review of the past and a glimpse into the future: from cell-cycle control to transcriptional regulation.
Sexl et al., Vienna, Austria. In Oncogene, Nov 2015
UNASSIGNED: The G1 cell-cycle kinase CDK6 has long been thought of as a redundant homolog of CDK4.
Palbociclib in Hormone-Receptor-Positive Advanced Breast Cancer.
PALOMA3 Study Group et al., Melbourne, Australia. In N Engl J Med, Aug 2015
BACKGROUND: Growth of hormone-receptor-positive breast cancer is dependent on cyclin-dependent kinases 4 and 6 (CDK4 and CDK6), which promote progression from the G1 phase to the S phase of the cell cycle.
Targeted Therapies Overcoming Endocrine Resistance in Hormone Receptor-Positive Breast Cancer.
Schmidt et al., Mainz, Germany. In Breast Care (basel), Jul 2015
Study results clearly show that both inhibition of the PI3K/AKT/mTOR pathway and CDK4/6 are promising ways to improve the efficacy of endocrine treatment in ER-positive breast cancer patients with comparably few side effects.
The history and future of targeting cyclin-dependent kinases in cancer therapy.
Knudsen et al., Dallas, United States. In Nat Rev Drug Discov, Feb 2015
In particular, cyclin-dependent kinases (CDKs) that promote transition through the cell cycle were expected to be key therapeutic targets because many tumorigenic events ultimately drive proliferation by impinging on CDK4 or CDK6 complexes in the G1 phase of the cell cycle.
The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study.
Slamon et al., Los Angeles, United States. In Lancet Oncol, 2015
BACKGROUND: Palbociclib (PD-0332991) is an oral, small-molecule inhibitor of cyclin-dependent kinases (CDKs) 4 and 6 with preclinical evidence of growth-inhibitory activity in oestrogen receptor-positive breast cancer cells and synergy with anti-oestrogens.
CDK4/6 Inhibitor PD0332991 in Glioblastoma Treatment: Does It Have a Future?
McDonald et al., Rotterdam, Netherlands. In Front Oncol, 2014
A specific CDK4/6 inhibitor, PD0332991, obtained accelerated approval from the Food and Drug Administration for the treatment of patients with advanced estrogen receptor-positive and HER2-negative breast cancer.
Promising rationally derived combination therapy with PI3K and CDK4/6 inhibitors.
Mills et al., Boston, United States. In Cancer Cell, 2014
In this issue of Cancer Cell, Vora and colleagues demonstrate that persistent CDK4 and pRB activation underlie acquired resistance to phosphatidylinositol 3-kinase (PI3K) inhibitors in breast cancer cell lines, suggesting that clinical evaluation of rational combination therapy with PI3K and CDK4/6 inhibitors to mitigate resistance to PI3K inhibition is warranted.
Cyclin D1-Cdk4 controls glucose metabolism independently of cell cycle progression.
Puigserver et al., Boston, United States. In Nature, 2014
Here we report that in mice insulin activates cyclin D1-cyclin-dependent kinase 4 (Cdk4), which, in turn, increases GCN5 acetyltransferase activity and suppresses hepatic glucose production independently of cell cycle progression.
Modification of the DNA damage response by therapeutic CDK4/6 inhibition.
Knudsen et al., Philadelphia, United States. In J Biol Chem, 2012
CDK4/6 inhibition can antagonize cytotoxic therapeutic strategies and increases utilization of error-prone DNA repair mechanisms that could contribute to disease progression.
Immunohistochemical investigation of F344/N rat islet cell tumors from national toxicology program studies.
Hoenerhoff et al., United States. In Toxicol Pathol, 2012
Islet cell tumors were associated with increased nuclear expression of cyclin-dependent kinase 4 as well as increased proliferating cell nuclear antigen and decreased beta-catenin expression.
Loss of Cdk2 and Cdk4 induces a switch from proliferation to differentiation in neural stem cells.
Kaldis et al., Singapore, Singapore. In Stem Cells, 2012
Data demonstrate the induction of neurogenic divisions in the absence of critical mediators of G1/S transition-Cdk2 and Cdk4, and highlight their evolutionary importance in the determination of cortical thickness.
p16-Cdk4-Rb axis controls sensitivity to a cyclin-dependent kinase inhibitor PD0332991 in glioblastoma xenograft cells.
Sarkaria et al., Rochester, United States. In Neuro Oncol, 2012
CDK4 amplification is associated with drug sensitivity in glioblastoma.
Yin Yang-1 inhibits tumor cell growth and inhibits p21WAF1/Cip1 complex formation with cdk4 and cyclin D1.
Khachigian et al., Sydney, Australia. In Int J Oncol, 2012
YY1 inhibited p21WAF1/Cip1 complex formation with cdk4 and cyclin D1 to prevent tumor growth.
More papers using CDK4 antibodies
Differential roles of two tandem E2F sites in repression of the human p107 promoter by retinoblastoma and p107 proteins
Hamel Paul A. et al., In The Journal of Cell Biology, 1994
... anti–E2F-2 (SC-633), anti–E2F-3 (SC-878), anti–E2F-4 (SC-866), anti–E2F-5 (SC-999), anti–cyclin E (SC-481), anti–cyclin A (SC-596), anti-cdk2 (SC-163), and anti-cdk4 (SC-749) polyclonal antibodies were purchased from Santa Cruz Biotechnology, Inc ...
Chlorpromazines and cancer
Rho Seung Bae et al., In Apoptosis, 1971
... study: anti-Akt, anti-phospho-specific Akt, anti-PI3K, anti-phospho-specific PI3K, anti-cyclin A, anti-cyclin B1, anti-cyclin D1, anti-CDK1, anti-CDK2, anti-CDK4 (Santa Cruz Biotechnology, Santa Cruz, CA), anti-caspase-3, ...
share on facebooktweetadd +1mail to friends